A secondary analysis of TRAILBLAZER-ALZ 2 strengthens the case that reducing amyloid plaques underlies the clinical benefits of donanemab in early Alzheimer’s disease.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/more-evidence-lowering-amyloid-clinically-beneficial-early-2025a1000s05?src=rss
Author :
Publish date : 2025-10-16 13:27:00
Copyright for syndicated content belongs to the linked Source.